tbuckley/cabot-search huggingface dataset:
Abstract 2169: Integrated proteomic and genomic profiling data from a tongue squamous cell carcinoma cell line separates normal and tumor tongue tissue
Authors: Rebecca Ceder, Claudia A. Staab, Karin Roberg, Hans Jörnvall, Jan-Olov Höög, Roland C. Grafström
Journal: Cancer Research (2010)

Abstract In depth characterization of individual human tumor cell lines might serve to explore the concept of future personalized cancer management. To address this question, standardized serum-free cultures of normal oral keratinocytes (NOK) were compared relative to the tongue squamous cell carcinoma line LK0412 via multiple bioinformatics-based assessments of transcript and protein profiles. Two-dimensional polyacrylamide electrophoresis identified 27 differentially expressed abundant proteins in LK0412. Gene Ontology enrichment analysis indicated alterations of the regulation of cell death, protein metabolism, energy pathways and various binding activities. Based on the protein-enriched GO-categories, the web-based program AffyAnnotator conducted the selection of 119 differently expressed transcripts from the microarray data in LK0412 vs. NOK. Ingenuity Pathway Analysis of these pertubated transcripts then revealed associations to cancer, cellular assembly and organization as well as cellular movement, and moreover, identified an 11-gene profile composed of central regulators within the networks. Notably, the differently expressed proteins and transcripts, as well as the 11-gene profile, variably classified two independent public microarray data sets of totally 38 normal and 57 tumor tongue samples, including a power of 95% accuracy from the 11-gene profile. Additional evaluation of the derived signatures by so called “signature evaluation tool” (implementing the Golub's weighted voting algorithm), identified reduced gene number signatures that similarly discriminated the normal from the tongue tissues in both data sets up to an accuracy rate of 95%. The overall results suggest that combined bioinformatics processing of transcript and protein data might serve as a constructive strategy for identification of potential candidate biomarkers in individual tumor samples, that may then serve to aid in cancer management. Additionally, gene signature profiles, generated as described, may serve to improve current efforts to accurately classify normal and tumor tongue tissues. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2169.
Women's Work: Occupational Cancer Risks Investigated at International Conference
Authors: N. Volkers
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Women's Work: Occupational Cancer Risks Investigated at International Conference Get access Nancy Volkers Nancy Volkers Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 23, 1 December 1993, Pages 1895–1897, https://doi.org/10.1093/jnci/85.23.1895 Published: 01 December 1993
The health service is more intent on cure than on care
Authors: J. R. Hughes
Journal: BMJ (2012)

Heath makes some excellent points.1 The fundamental problem is that the NHS has not kept pace with the demographic change in society. The needs of vulnerable, usually elderly, patients and those approaching the end of their lives are being sidelined in a health service that is more intent on cure than on care. As Heath states, the gaps through which vulnerable …
SAT0228 Study of the disease activity and refractoriness to the treatment in a large spanish multicentric cohort of patients with systemic lupus erythematosus:
Authors: J. Pego-Reigosa, I. Rúa, B. Aspe, M. Galindo, J. Lόpez-Longo, J. Calvo, M. García-Yebenes, E. Tomero, E. Uriarte, C. Fito, A. Sánchez, A. Olivé, C. Montilla, J. Rosas
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> There is little information about the level of activity and the refractoriness to the treatment of the SLE patients in Spain. <h3>Objectives</h3> To study the level of activity and calculate the percentage of SLE patients who are refractory to the therapies. <h3>Methods</h3> <i>Patients</i>. SLE patients from the RELESSER Registry with active follow up in a Rheumatology Department. <b>Variables</b>. a) clinical and analytical activity manifestations and b) past and current treatments. <b>Methods</b>. Retrospective study of the data collected at the time of the last evaluation of the patient. a) the SELENA-SLEDAI score is calculated and the SLE activity stratified according to that score, b) the percentage of refractory cases is calculated according to predefined criteria: inefficacyof cyclophosphamide (CYC), use of rituximab, splenectomy or inefficacy of ≥2 immunosupressors (methotrexate, leflunomide, abatacept, anti-TNF, azathioprine, CYC, mycophenolate mofetil and/or mycophenolic acid). <h3>Results</h3> 583 patients were included (88.3% females, mean age: 45.5 years, SLE duration: median 111 months). At the time of the study, the most frequent clinical manifestations of activity were mucocutaneous (13.9%) and musculoskeletal (6.3%). The least frequent clinical features were myositis and psychosis (0% both). There was renal or neurological/psychiatric activity in the 7.8% and 2.3% of the patients, respectively. From the analytical perspective, 13.6% of the patients had leukopenia. 27 (4.6%) patients had hypocomplementemia and anti-dsDNA antibodies without any clinical manifestation. The median SLEDAI score was: 2 (range: 0-23). 39.4% of patients had a SLEDAI score =0. SLE disease activity was mild (1-4 points), moderate (5-9) and severe (≥10) in 43.4, 13.2 and 3.9% of patients, respectively. The table shows the treatments for lupus that received the patients in each activity level group. 59 (10.1%) of the patients presented moderate or severe activity in spite of being on corticosteroid and antimalarial treatment. The percentage of refractoriness, according to the definition in the "Methods" section, was 10.3% of the patients. <h3>Conclusions</h3> The level of disease activity of the lupus patients followed in Spanish Rheumatology Departments is relatively low. An important percentage of the patients (10.1%) has moderate-severe lupus activity in spite of the use of corticosteroids and antimalarials. The percentage of refractoriness of the SLE might be about the 10% of the patients. <h3>Disclosure of Interest</h3> None Declared
GW25-e4220 Comparison of two methods for evaluating human carotid artery elasticity: Possible detection of early atherosclerosis In subjects with dyslipidemia
Authors: Zhang Yanling, Niu Lili, Zheng Hairong, Liu Jinlai, Zhang Hui, Xu Shicheng, Zheng Rongqin
Journal: Journal of the American College of Cardiology (2014)
Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study.
Authors: A. Dasari, Alexandria T. Phan, Martyn E. Caplin, Marianne E. Pavel, Jaroslaw B Cwikla, Markus Raderer, Eva Sedlackova, Guillaume Cadiot, Edward M. Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Edda Gomez-Panzani, Philippe B. Ruszniewski
Journal: Journal of Clinical Oncology (2015)

4104 Background: In CLARINET, progression-free survival (PFS) was significantly prolonged with the somatostatin analog LAN 120 mg vs. placebo in patients with metastatic grade 1 or 2 (Ki-67 <10%) non-functioning intestinal and pancreatic NETs (hazard ratio [HR] for progressive disease [PD]/death: 0.47 [95% CI: 0.30, 0.73]. Here, we more fully characterize treatment effects in the midgut subgroup (tumors of small intestine/appendix). Methods: CLARINET was a 96-week randomized double-blind trial. Patients received LAN 120 mg or placebo every 4 weeks, administered by deep subcutaneous injection (NCT00353496). Subgroup analyses were undertaken to investigate only the consistency of treatment effects as the study was not otherwise designed or powered for such analyses. Results: 73 patients with midgut NETs received LAN (n=33) or placebo (n=40). At baseline, mean age was 64 yrs, 34% had liver burdens >10% (19% with burdens >25%), 96% had stable disease, 88% had received no previous treatment, and 48% had undergone previous NET surgery. Median PFS in the midgut subgroup was not reached at study end with lanreotide vs. 21 months with placebo; treatment response was consistent in midgut NETs with liver tumor burdens above or below 10% (Table). Adverse events occurred at similar rates with lanreotide vs placebo (overall: 85 vs 93%; treatment-related: 42 vs 33%). Few patients on LAN or placebo had serious AEs (n=5 vs n=7; none treatment-related) or AE-related withdrawal (n=0 vs n=1). Conclusions: These data indicate antitumor effects and a favourable safety/tolerability profile that support LAN as a first-line midgut NET treatment. This is consistent with previous reports in the overall CLARINET study population. Clinical trial information: NCT00353496. Midgut NET patients N LAN PFS* PBO PFS* Logrank p-value HR (95% CI) All 73 Not reached 85 wks p=0.009 0.35 (0.16, 0.80) Liver burden ≤10% 48 Not reached 98 wks p=0.044 0.30 (0.08, 1.04) Liver burden >10% 25 Not reached 60 wks p=0.007 0.21 (0.06, 0.72) *Median PFS estimated by Kaplan-Meier method.
Abstract 957: Dietary flavonols protect against colorectal carcinogenesis in an AOM-DSS mouse model for colorectal cancer
Authors: Gerd Bobe, Matthew R. Young, Young Kim, Nancy H. Colburn
Journal: Cancer Research (2010)

Abstract Background: Epidemiological studies suggest that a flavonol-rich diet inhibits colorectal carcinogenesis. Flavonols are a subgroup of polyphenols, which are found in fruits and vegetables usually glycosylated and are in particularly high concentrations in dry beans, onions, apples, and tea. The most consumed individual flavonols are in this order quercetin and one of its glycosylated forms rutin, kaempferol, myricetin, and isorhamnetin. Aim: To determine which individual flavonol is most protective against colorectal carcinogenesis in an inflammation-associated mouse colorectal carcinogenesis model (azoxymethane[AOM]/dextran sodium sulfate[DSS]-induced FVB mice). Methods: At 6 weeks of age, mice were injected intraperitoneally with AOM (10 mg/kg body weight). Mice then received for 1 week 2% DSS in the drinking water (1 or 1 and 4 weeks after AOM injection). Three days after the last DSS cycle, mice either remained on the AIN-93G diet or were switched to one enriched with 500 mg of kaempferol or equimolar concentrations of isorhamnetin, myricetin, quercetin, or rutin/kg of diet. Mice (n=32/group) remained for 85 days on the diets unless they had to be sacrificed earlier because of morbidity. A subset of mice was imaged using magnetic resonance imaging (MRI) at various times throughout the study. Results: Among the diets, mice on the control diet had the highest morbidity (50%) and mice on the isorhamnetin diet had the lowest morbidity (22%). Similarly, lesion number and size were lowest in mice on the isorhamnetin (16/mouse and 8.8 mm3/lesion) and the kaempferol (15/mouse and 7.4 mm3/lesion) diet compared to the control diet (21/mouse and 11.6 mm3/lesion). Image parameters detected different stages of colorectal carcinogenesis that can be modified by diet. Conclusion: All individual flavonols showed some protection against colorectal carcinogenesis with isorhamnetin and kaempferol being most efficacious. Studies are underway to identify serum, tissue, and imaging biomarkers of efficacy at earlier stages of colorectal carcinogenesis. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 957.
Uptake of Tc-99m Sestamibi and Tc-99m MDP in Anaplastic Carcinoma of the Thyroid (Nondiagnostic CT and Ultrasound Scans)
Authors: T. CELSO MONTES, CARLOS MUÑOZ, J. IGNACIO RIVERO, J. ANTONIO MOTA, NINA PUSTILNIK, FERNANDO GARCIA
Journal: Clinical Nuclear Medicine (1999)

A 63-year-old woman with hypothyroid disease was undergoing treatment with thyroid hormone. She had a bone scan for generalized bone pain and weight loss. The scan revealed a lytic lesion in the skull. Later a Tc-99m sestamibi scan showed thyroid uptake and infiltration into the neck structures. She underwent neck surgery with transoperative biopsy, which revealed anaplastic carcinoma, so a thyroidectomy was not performed. The surgical findings of the neck architecture were similar to those observed on the Tc-99m sestamibi scan. The skull radiograph, CT, and bone scan showed a skull lesion. CT and ultrasound of the neck revealed only atrophic changes (not diagnostic). The histopathologic findings of the skull biopsy were identical to those of the neck. The patient died 2 weeks after diagnosis.
Subperiosteal Bone Resorption
Authors: Takafumi Taguchi, Yoshio Terada
Journal: New England Journal of Medicine (2014)

A 45-year-old man was admitted to the hospital with anorexia, fatigue, and thirst. About 10 years earlier, he had been treated for urinary calculi. Evaluation showed an elevated serum calcium level and a serum intact PTH level of 3844 pg per milliliter (normal range, 10.3 to 65.9).
UTILIDAD DE LA ULTRASONOGRAFÍA ENDOSCÓPICA (USE) EN LA ESTADIFICACIÓN DEL CÁNCER DE RECTO (CR). EXPERIENCIA EN EL HOSPITAL 12 DE OCTUBRE DE MADRID
Authors: M Pérez-Carreras, J Díaz-Tasende, JC Marín-Gabriel, I Salces, D Lora, F Colina-Ruizdelgado, C López, S Rodríguez-Muñoz, G Castellano-Tortajada
Journal: Endoscopy (2012)

Introducción. La USE endorrectal es una técnica aceptada para la estadificación locorregional del CR. Su utilidad puede verse afectada por la curva de aprendizaje y el tiempo de demora quirúrgico. Material y método: Estudio retrospectivo de 147 USE en pacientes con CR entre junio-2008 y junio-2012, entre las que se seleccionaron aquellos CR resecados sin neoadyuvancia. Se utilizó la clasificación TNM (uT y uN en el informe de la ecoendoscopia, pT y pN en el del patólogo). Calculamos el grado de acuerdo (coeficiente Kappa) entre uT/pT y uN/pN en el grupo de pacientes sin neoadyuvancia. Se analizó el papel de la curva de aprendizaje comparando los resultados en 2 subgrupos (antiguo y reciente), según la fecha de la USE, y los cambios de acuerdo según el tiempo de demora quirúrgico. Resultados: Se incluyeron 55/147 (37%) pacientes intervenidos sin neoadyuvancia (20 mujeres/35 hombres; edad media: 68±13 años), el 85% (47/55) con CR distal. Los estadios más frecuentes fueron uT3 y pT3 (47 y 55%, respectivamente), seguidos de uT2/pT2 (40 y 33%), uT1/pT1 (7%) y uT4/pT4 (5%). Encontramos uN en 17/55 (31%) pacientes y pN en 28/55 (51%). En el 84% de casos coincidieron uT y pT (46/55), con un grado de acuerdo 0.75 (0.60–0.91); para uN/pN el acuerdo fue 0,40 (0.16–0.60). La S, E y VPP para uT1 fueron: 75, 98 y 75%; T2: 72, 84 y 73%; uT3:80,92 y 92%; uT4:100,100 y 100%. Obtuvimos mayor acuerdo entre las 27/55 USE del periodo cercano a 2012 (subgrupo reciente) vs. 28/55 USE cercanas a 2008 (subgrupo antiguo): uT1 (1 vs. 0,62); uT 2 (0,72 vs. 0,61); uT3 (0,72 vs. 0,70). El acuerdo uT/pT fue superior en los CR intervenidos antes de los 2 meses (0.77 vs. 0.62), siendo la diferencia significativa en uT3 (0,75 vs. 0,17; p>0,05. Conclusiones: 1. El 85% de CR son de localización distal y cerca del 50% presentan infiltración de la grasa perirrectal en el momento del diagnóstico (uT3/pT3); 2. La USE ofrece un grado de acuerdo uT/pT “bueno” y uN/pN “ligero”; 4. El acuerdo de uT/pT mejora cuando el número de exploraciones es próximo a 30; 5. La utilidad de la USE en la estadificación del CR empeora cuando la demora quirúrgica es mayor de 2 meses.
AG-024322 is a potent and selective multi-targeted CDK inhibitor with broad spectrum anti-proliferative activity
Authors: Cathy C. Zhang, Susan Kephart, Indrawan McAlpine, Jim Nonomiya, Joseph Higgins, Maria E. Arango, Zhengming Yan, Daniel Knighton, Rose Ann Ferre, Jayashree Tikhe, Gennady Verkhivker, Meirong Xu, William Romines, Cindy Palmer, Julie Park, Siegfried Reich, Wes Chong, Lin Li, Gerrit Los, Cristina Lewis
Journal: Cancer Research (2005)

4415  Uncontrolled cell proliferation is the hallmark of cancer, and is typically manifested by a de-regulation of the cell-division cycle. Cyclin-dependent-kinases (CDKs) play critical roles in regulating the cell cycle by phosphorylating several cellular proteins. The CDKs are de-regulated and activated in most (if not all) human cancers in a variety of ways, including down-regulation or inactivation of the endogenous CDK inhibitory proteins, overexpression of the essential cyclin subunits of the CDKs, and activating mutations in CDK substrates such as the Retinoblastoma (Rb) protein. The activation of CDKs in tumors highlights these enzymes as important cancer targets for novel therapeutic intervention. An integrated strategy of structure-based drug design and combinatorial chemistry efforts was used to optimize compounds with potent and selective inhibition of the major cell cycle kinases CDK1, CDK2 and CDK4. AG-024322 displays potent inhibition of these CDKs, with Ki’s in the 1-3 nM range and selectivity over a number of other kinases. This potent enzymatic inhibition translates to cellular activity, in that AG-024322 also inhibits Rb phosphorylation in cells. Potent antiproliferative activity was demonstrated in multiple human tumor cell lines, with IC50 values ranging from 30 to 200 nM. As expected for a multi-targeted (pan)-CDK inhibitor, AG-024322 causes arrest at multiple stages of the cell cycle. In addition, AG-024322 is cytotoxic and induces cell death by apoptosis in a time- and dose-dependent manner. These results identify AG-024322 as a potent, multi-targeted CDK inhibitor with broad spectrum anti-proliferative activity.
TIEMPO ÓPTIMO DE PERMANENCIA DE LAS PROTESIS BILIARES PLÁSTICAS EN CASOS DE EXTRACCION INCOMPLETA DE COLEDOCOLITIASIS
Authors: G Cacho Acosta, JM Fernández Font, S Agudo Fernández, M Fernández Gil, S Blasco Algora, CM Fernández Rodríguez
Journal: Endoscopy (2013)

Introducción: algunos casos de coledocolitiasis difíciles no se resuelven en la primera CPRE. El uso temporal de prótesis plásticas biliares antes de una nueva CPRE es una alternativa eficaz. Se desconoce el tiempo óptimo de permanencia de las prótesis antes de un nuevo intento de extracción. Objetivo: evaluar cuál es el período óptimo de permanencia de las prótesis biliares plásticas en los casos de extracción incompleta de coledocolitiasis antes del siguiente intento endoscópico. Material y Método: revisamos nuestra experiencia de los últimos siete años. Mediante una curva ROC evaluamos el efecto del tiempo de permanencia de la prótesis sobre la probabilidad de éxito posterior. Resultados: Se incluyeron 45 pacientes. Se efectuaron 104 CPRE (mediana 2, rango 2 – 5). En la primera CPRE se usaron prótesis de 10F en el 87% de los casos y de 7F en el resto. La prótesis se mantuvo una media de 90 días (rango 7 – 385). En el 73% de los casos las litiasis eran múltiples. Aparecieron complicaciones en 6 casos (3 colangitis, 2 hemorragias, 1 pancreatitis), sin mortalidad asociada. La tasa de éxito tras la segunda CPRE fue del 60%, que llegó al 80% en siguientes intentos. La experiencia del endoscopista, el número de litiasis o quien administró la sedación no influyeron significativamente en el éxito final. El análisis de la curva ROC para el intervalo de permanencia de la prótesis en la vía biliar y el éxito de la subsiguiente CPRE mostró dos puntos de maximización de sensibilidad y especificidad entre 53 y 90 días (área bajo la curva 0,59 ± 0.09). Conclusiones: La colocación temporal de una prótesis biliar plástica es una alternativa efectiva en el tratamiento de coledocolitiasis difíciles. En nuestra experiencia, el intervalo óptimo de permanencia de las prótesis en la vía biliar hasta el siguiente intento es dos a tres meses.
Subcapsular hepatic hematoma following ERCP: case report and review
Authors: D. Del Pozo, I. Moral, E. Poves, C. Sanz, M. Martín
Journal: Endoscopy (2011)

A 76-year-old woman, who was receiving anticoagulation for atrial fibrillation, was referred to our center for management of a common bile duct stone diagnosed by endoscopic ultrasonography. Anticoagulation was suspended and endoscopic retrograde cholangiopancreatography (ERCP) was subsequently performed. Cannulation of the main bile duct with a 0.035-inch guide wire was achieved without complications. Endoscopic biliary sphincterotomy was performed and stone extraction with a Fogarty catheter was achieved successfully, without apparent complications. Subsequently, the patient developed sharp right upper quadrant pain 6 hours after the procedure, but showed no signs of hemodynamic instability, and laboratory data did not show any evidence of complications. By 24-hours after the procedure, she was asymptomatic and was discharged after the reintroduction of anticoagulation.
OPTIMIZATION OF PLATELET RADIOLABELING USING 99mTECHNETIUM-HMPAO
Authors: T. Navaratnam, M. M. Dalipai, A. Jansson, T. Alvarez-Diez, T. D. Ruddy
Journal: Clinical Nuclear Medicine (1998)

Navaratnam, T.; Dalipai, M. M.; Jansson, A.; Alvarez-Diez, T.; Ruddy, T. D. Author Information
PARE0005 Summer Seminar Organized by Estonian RHEUMATISM Association for Patients with Rheumatic Diseases
Authors: K. Kokk
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> There are approximately 250 thousand people in Estonia who suffer from bone and join diseases at any stages. Patients with long-term chronic diseases have always been a priority in the Health Insurance Fund but due to that it also has a negative impact on government9s budget in general. This is because patients with chronic diseases are usually not capable of remaining active in laboring market. As an umbrella organization we have twelve sub-organizations with 819 members in total. The project is aimed at 100 active members, voulenteers, board members and management team, which offers all the participants to share experiences about rheumatic diseases, take part in lectures and communicate with eachother in general. One of main roles for organizing summer seminar is to bring provincial member associations together and offer them opportunity to make new relations. All the activities are divided between two days containing various lectures and workshops. Topics are even deeply discussed in workshops where participants can have immediate feedback. <h3>Objectives</h3> The summer seminar was held on 1-2nd november 2013. The main objective of the project is to improve quality of life among participants by educating them in topics related to bone and joint diseases etc. Secondly, it is necessary to improve cooperation between member organizations and professionals in order to enrich the knowledge about management and organizing projects. <h3>Methods</h3> Participants will have an opportunity to learn about alternative medicine for improving their health. All the topics are being treated in workshops and lectures. All the activites are mainly practical. <h3>Results</h3> About 100 people with various bone and joint diseases will become more aware about coping with the chronic diseases, which improves the overal quality of life for the participants. After the seminar, sub-organizations are more eager to work together with common problems and prepare projects to implement new ideas. <h3>Conclusions</h3> In conclusion, Estonian Rheumatism Association has an opportunity to gather feedback from the participants to improve the following events directed to our members. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5941